INmune Bio, Inc. (NASDAQ:INMB) Short Interest Update

INmune Bio, Inc. (NASDAQ:INMB) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totaling 3,896,241 shares, an increase of 20.2% from the December 31st total of 3,241,827 shares. Based on an average daily trading volume, of 342,062 shares, the days-to-cover ratio is presently 11.4 days. Approximately 18.6% of the company’s shares are short sold. Approximately 18.6% of the company’s shares are short sold. Based on an average daily trading volume, of 342,062 shares, the days-to-cover ratio is presently 11.4 days.

Hedge Funds Weigh In On INmune Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in INMB. XTX Topco Ltd raised its holdings in INmune Bio by 240.9% during the 2nd quarter. XTX Topco Ltd now owns 125,847 shares of the company’s stock worth $291,000 after buying an additional 88,928 shares during the period. Westside Investment Management Inc. increased its position in shares of INmune Bio by 384.0% during the third quarter. Westside Investment Management Inc. now owns 103,450 shares of the company’s stock worth $214,000 after acquiring an additional 82,075 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of INmune Bio by 1,042.7% during the second quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company’s stock worth $169,000 after acquiring an additional 66,700 shares during the period. PNC Financial Services Group Inc. bought a new stake in INmune Bio in the 2nd quarter valued at $87,000. Finally, Focus Partners Advisor Solutions LLC boosted its stake in INmune Bio by 321.2% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 48,813 shares of the company’s stock worth $113,000 after purchasing an additional 37,224 shares during the period. 12.72% of the stock is owned by institutional investors.

INmune Bio Stock Performance

INMB traded down $0.07 during midday trading on Wednesday, reaching $1.49. 182,563 shares of the company were exchanged, compared to its average volume of 331,306. The stock has a market capitalization of $39.47 million, a P/E ratio of -0.70 and a beta of 0.72. INmune Bio has a one year low of $1.38 and a one year high of $11.64. The stock’s 50-day simple moving average is $1.71 and its 200 day simple moving average is $1.94.

Analyst Upgrades and Downgrades

INMB has been the subject of a number of recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of INmune Bio in a research report on Wednesday, October 8th. Wall Street Zen raised INmune Bio from a “sell” rating to a “hold” rating in a report on Sunday, December 14th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $15.50.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.